Seok-Ho Yoon1, Ku Sang Kim2, Seok Yun Kang3, Hee-Sung Song1, Kyung Sook Jo1, Bong-Hoi Choi4, Su Jin Lee1, Joon-Kee Yoon1, Young-Sil An1. 1. Department of Nuclear Medicine and Molecular Imaging, Ajou University School of Medicine, San 5, Wonchon-dong, Yeongtong-gu, Suwon, Kyunggi-do Republic of Korea 443-721. 2. Department of Surgery, Ajou University School of Medicine, San 5, Wonchon-dong, Yeongtong-gu, Suwon, Kyunggi-do Republic of Korea 443-721. 3. Department of Hematology-Oncology, Ajou University School of Medicine, San 5, Wonchon-dong, Yeongtong-gu, Suwon, Kyunggi-do Republic of Korea 443-721. 4. Clinical Research Institute, Gyeongsang National University Hospital, Chiram-dong, Jinju Si, Gyeongsangnam-Do Republic of Korea 660-702.
Abstract
PURPOSE: Bone metastasis is an important factor for the treatment and prognosis of breast cancer patients. Whole-body bone scintigraphy (WBBS) can evaluate skeletal metastases, and (18)F-FDG PET/CT seems to exhibit high specificity and accuracy in detecting bone metastases. However, there is a limitation of (18)F-FDG PET in assessing sclerotic bone metastases because some lesions may be undetectable. Recent studies showed that (18)F-fluoride PET/CT is more sensitive than WBBS in detecting bone metastases. This study aims to evaluate the usefulness of (18)F-fluoride PET/CT by comparing it with WBBS and (18)F-FDG PET/CT in breast cancer patients with osteosclerotic skeletal metastases. MATERIALS AND METHODS: Nine breast cancer patients with suspected bone metastases (9 females; mean age ± SD, 55.6 ± 10.0 years) underwent (99m)Tc-MDP WBBS, (18)F-FDG PET/CT and (18)F-fluoride PET/CT. Lesion-based analysis of five regions of the skeletons (skull, vertebral column, thoracic cage, pelvic bones and long bones of extremities) and patient-based analysis were performed. RESULTS: (18)F-fluoride PET/CT, (18)F-FDG PET/CT and WBBS detected 49, 20 and 25 true metastases, respectively. Sensitivity, specificity, positive predictive value and negative predictive value of (18)F-fluoride PET/CT were 94.2 %, 46.3 %, 57.7 % and 91.2 %, respectively. Most true metastatic lesions on (18)F-fluoride PET/CT had osteosclerotic change (45/49, 91.8 %), and only four lesions showed osteolytic change. Most lesions on (18)F-FDG PET/CT also demonstrated osteosclerotic change (17/20, 85.0 %) with three osteolytic lesions. All true metastatic lesions detected on WBBS and (18)F-FDG PET/CT were identified on (18)F-fluoride PET/CT. CONCLUSION: (18)F-fluoride PET/CT is superior to WBBS or (18)F-FDG PET/CT in detecting osteosclerotic metastatic lesions. (18)F-fluoride PET/CT might be useful in evaluating osteosclerotic metastases in breast cancer patients.
PURPOSE: Bone metastasis is an important factor for the treatment and prognosis of breast cancerpatients. Whole-body bone scintigraphy (WBBS) can evaluate skeletal metastases, and (18)F-FDG PET/CT seems to exhibit high specificity and accuracy in detecting bone metastases. However, there is a limitation of (18)F-FDG PET in assessing sclerotic bone metastases because some lesions may be undetectable. Recent studies showed that (18)F-fluoride PET/CT is more sensitive than WBBS in detecting bone metastases. This study aims to evaluate the usefulness of (18)F-fluoride PET/CT by comparing it with WBBS and (18)F-FDG PET/CT in breast cancerpatients with osteosclerotic skeletal metastases. MATERIALS AND METHODS: Nine breast cancerpatients with suspected bone metastases (9 females; mean age ± SD, 55.6 ± 10.0 years) underwent (99m)Tc-MDPWBBS, (18)F-FDG PET/CT and (18)F-fluoride PET/CT. Lesion-based analysis of five regions of the skeletons (skull, vertebral column, thoracic cage, pelvic bones and long bones of extremities) and patient-based analysis were performed. RESULTS: (18)F-fluoride PET/CT, (18)F-FDG PET/CT and WBBS detected 49, 20 and 25 true metastases, respectively. Sensitivity, specificity, positive predictive value and negative predictive value of (18)F-fluoride PET/CT were 94.2 %, 46.3 %, 57.7 % and 91.2 %, respectively. Most true metastatic lesions on (18)F-fluoride PET/CT had osteosclerotic change (45/49, 91.8 %), and only four lesions showed osteolytic change. Most lesions on (18)F-FDG PET/CT also demonstrated osteosclerotic change (17/20, 85.0 %) with three osteolytic lesions. All true metastatic lesions detected on WBBS and (18)F-FDG PET/CT were identified on (18)F-fluoride PET/CT. CONCLUSION: (18)F-fluoride PET/CT is superior to WBBS or (18)F-FDG PET/CT in detecting osteosclerotic metastatic lesions. (18)F-fluoride PET/CT might be useful in evaluating osteosclerotic metastases in breast cancerpatients.
Entities:
Keywords:
18F-NaF; 18F-fluoride; Breast cancer; PET/CT; Skeletal metastases
Authors: H Schirrmeister; G Glatting; J Hetzel; K Nüssle; C Arslandemir; A K Buck; K Dziuk; A Gabelmann; S N Reske; M Hetzel Journal: J Nucl Med Date: 2001-12 Impact factor: 10.057
Authors: James L Khatcheressian; Antonio C Wolff; Thomas J Smith; Eva Grunfeld; Hyman B Muss; Victor G Vogel; Francine Halberg; Mark R Somerfield; Nancy E Davidson Journal: J Clin Oncol Date: 2006-10-10 Impact factor: 44.544
Authors: M Petrén-Mallmin; I Andréasson; O Ljunggren; H Ahlström; J Bergh; G Antoni; B Långström; M Bergström Journal: Skeletal Radiol Date: 1998-02 Impact factor: 2.199
Authors: Tsuyoshi Hamaoka; John E Madewell; Donald A Podoloff; Gabriel N Hortobagyi; Naoto T Ueno Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Martin Hetzel; Coskun Arslandemir; Hans-Helmut König; Andreas K Buck; Karin Nüssle; Gerhard Glatting; Andreas Gabelmann; Jürgen Hetzel; Vinzenz Hombach; Holger Schirrmeister Journal: J Bone Miner Res Date: 2003-12 Impact factor: 6.741
Authors: Lanell M Peterson; Janet O'Sullivan; Qian Vicky Wu; Alena Novakova-Jiresova; Isaac Jenkins; Jean H Lee; Andrew Shields; Susan Montgomery; Hannah M Linden; Julie Gralow; Vijayakrishna K Gadi; Mark Muzi; Paul Kinahan; David Mankoff; Jennifer M Specht Journal: J Nucl Med Date: 2018-05-10 Impact factor: 10.057
Authors: E L Gerety; E M Lawrence; J Wason; H Yan; S Hilborne; J Buscombe; H K Cheow; A S Shaw; N Bird; K Fife; S Heard; D J Lomas; A Matakidou; D Soloviev; T Eisen; F A Gallagher Journal: Ann Oncol Date: 2015-07-22 Impact factor: 32.976